Merck's Efinopegdutide Shows Improvement In Liver Fibrosis Without Worsening Steatohepatitis
Nov 9 (Reuters) - Merck & Co Inc MRK.N:
MERCK ANNOUNCES POSITIVE RESULTS FROM PHASE 2B TRIAL OF EFINOPEGDUTIDE IN ADULTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND STAGE 2-3 FIBROSIS
MERCK & CO - EFINOPEGDUTIDE DEMONSTRATES IMPROVEMENT IN LIVER FIBROSIS WITHOUT WORSENING STEATOHEPATITIS
MERCK & CO - EFINOPEGDUTIDE SHOWS SIGNIFICANT MASH RESOLUTION WITHOUT FIBROSIS WORSENING AT 52 WEEKS
Further company coverage: MRK.N